3 Underappreciated Pharma Stocks
With manageable patent-loss exposures and strong pipelines, Big Pharma is the best positioned it has been since 2005.
With manageable patent-loss exposures and strong pipelines, Big Pharma is the best positioned it has been since 2005.
Damien Conover: We've just completed a deep-dive analysis on the large-cap pharmaceutical space. From our analysis, we think the group is the best position it has been since 2005, and this has a lot to do with the lack of patent losses coming up for this group.
If you look back at the major patent cliff of 2012, that's finally behind the group. A lot of patents have annualized off. As we look forward, there's not a lot of patent exposure coming up. The group also has very strong pipelines aimed at areas of unmet medical need where products have very strong pricing power and regulatory agencies are more likely to approve the drugs. With this in mind, there are some stocks we think are still underappreciated even though the rest of the group has appreciated a lot over the last two to three years.
The three names we're guiding investors to are Merck (MRK), Bristol (BMY), and Sanofi (SNY)--all three of which have pipelines that are underappreciated and have patent exposure that we think is manageable. This sets these firms up for nice capital appreciation as well as strong dividend yields that should augment the capital appreciation with each one of these stocks.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.